Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition
Related Experiment Video
Updated: May 1, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Stanley R Riddell1, Daniel Sommermeyer, Carolina Berger
1From the Fred Hutchinson Cancer Research Center, Seattle, WA.
Abstract:
The ability to engineer T cells to recognize tumor cells through genetic modification with a synthetic chimeric antigen receptor has ushered in a new era in cancer immunotherapy. The most advanced clinical applications are in targeting CD19 on B-cell malignancies. The clinical trials of CD19 chimeric antigen receptor therapy have thus far not attempted to select defined subsets before transduction or imposed uniformity of the CD4 and CD8 cell composition of the cell products. This review will discuss the rationale for and challenges to using adoptive therapy with genetically modified T cells of defined subset and phenotypic composition.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for cancer immunotherapy, particularly for B-cell malignancies targeting CD19. This review explores challenges and rationale for using defined T-cell subsets in CAR T-cell therapy.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Engineering
Background:
- Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in cancer immunotherapy.
- Current clinical applications primarily focus on targeting CD19 for B-cell malignancies.
Purpose of the Study:
- This review discusses the rationale for and challenges associated with employing genetically modified T cells with defined subset and phenotypic composition in adoptive therapy.
- It highlights the need for greater uniformity in CAR T-cell products.
Main Methods:
- Literature review of current CAR T-cell therapy trials and research.
- Analysis of the implications of T-cell subset selection and composition.
Main Results:
- Clinical trials have not consistently selected defined T-cell subsets before transduction.
- There is a lack of uniformity in the CD4 and CD8 cell composition of current CAR T-cell products.
Conclusions:
- Selecting defined T-cell subsets and ensuring phenotypic uniformity are critical for optimizing CAR T-cell therapy efficacy and safety.
- Further research is needed to overcome the challenges in achieving consistent and defined T-cell product composition for improved cancer treatment outcomes.
